Drugs Made In America Acquisition II Corp.
Searching since IPO 2025-09-25- CIK 2040475
- DMII
- IPO 2025-09-25
- $514M trust
- 45 filings
Filings, by quarter
45 filings over 7 quarters; dark bars carry a milestone
- 25 Q1: 1 filing
- 25 Q2: 4 filings
- 25 Q3: 20 filings
- 25 Q4: 11 filings
- 26 Q1: 3 filings
- 26 Q2: 5 filings
- 26 Q3: 1 filing
S-1 filed
IPO
- S-1 filed 25 Q1
- IPO 25 Q3
SPAC Overview
$500M
IPO Size
$514M
Trust (as of 2026-06-30)
IPO
Current Status
2025
IPO Year
Timeline Progress
About
Drugs Made In America Acquisition II Corp. is a blank-check company seeking to complete an initial business combination, with a stated focus on the pharmaceutical sector. Its strategy is to acquire and support the growth of a U.S. pharmaceutical business.
Investment Focus
Biopharmaceuticals
Geographic Focus
United States
Key Information
IPO Date
2025-09-25
SIC
6770
SPAC Ticker
DMII
Stock Performance
DMIIU
Trading Symbol
First Trade
2025-09-25
$9.98
Current Price
2026-10-01
$10.20
+2%
SPAC Team
Underwriters
Extended Team Information
The team includes Lynn Stockwell, an executive with pharmaceutical and healthcare experience; Glenn Worman, a financial executive with prior SPAC CFO experience; and director nominees Catherine Do, G. Sridhar Prasad, and Myron W. Shulgan, whose backgrounds include drug discovery, biomedical research, and legal practice.